Some researchers think that tumor heterogeneity may play a role.30 It has been widely reported that there is a correlation between BRAF mutation and poor prognosis in CRC patients, especially in advanced stage.33 A pooled study of three randomized clinical trials showed worse outcome of OS for BRAF mutation patients, but the DFS and progression‐free survival (PFS) were comparable to those without BRAF mutation.34 The OS of patients with BRAF mutation also seems to be worse in our study (49.9 m vs 83.2 m). The gene discussed is BRAF; the disease is colorectal carcinoma.